Last week, I gave four reasons why I was happy to be skipping J.P. Morgan this year. I should have given a fifth: 90% of the dialogue around #JPM25 --
The idea that hospitals are marking up prices on medicines -- not by a little, but by a whole lot -- is not a new one. PhRMA has been waving
I often act all exasperated when data emerges that shows that the net prices of medicines are going down, feigning frustration at the fact that there has been limited recognition